• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 3681-99-0 Price $30 / 20mg
    Catalog No.CFN99169Purity>=98%
    Molecular Weight416.38Type of CompoundFlavonoids
    FormulaC21H20O9Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Universita' Degli Studi Di Cagli... (Italy)
  • Sant Gadge Baba Amravati Univers... (India)
  • Heidelberg University (Germany)
  • University of Perugia (Italy)
  • Universidade Federal de Pernambu... (Brazil)
  • Heinrich-Heine-University Düsse... (Germany)
  • Charles Sturt University (Denmark)
  • Instituto de Investigaciones Agr... (Chile)
  • University of Canterbury (New Zealand)
  • Leibniz-Institut für Pflanzenbi... (Germany)
  • University of Sao Paulo (Brazil)
  • More...
  • Package
    Featured Products

    Catalog No: CFN92302
    CAS No: 24159-07-7
    Price: $258/10mg

    Catalog No: CFN98423
    CAS No: 3301-49-3
    Price: $238/10mg

    Catalog No: CFN99306
    CAS No: 119400-87-2
    Price: $398/5mg

    Catalog No: CFN99710
    CAS No: 51059-44-0
    Price: $100/20mg
    Terrestrosin K

    Catalog No: CFN90822
    CAS No: 193605-07-1
    Price: $268/10mg
    Biological Activity
    Description: Puerarin is a 5-HT2C receptor and benzodiazepine site antagonist, it exerts a regulatory effect on lipid accumulation by decreasing lipogenesis in hepatocytes, it may have therapeutic benefits in the treatment of fatty liver and lipid-related metabolic disorders, it also may act as an intracellular ROS scavenger, and its antioxidant properties may protect against Abeta25-35-induced cell injury,and apoptosis and could also promote the survival of PC12 cells.
    Targets: PPAR | AMPK | IL Receptor | NOS | PI3K | Akt | ROS | Bcl-2/Bax | Beta Amyloid | P450 (e.g. CYP17)
    In vitro:
    Int J Mol Med. 2015 Mar;35(3):803-9.
    Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.[Pubmed: 25605057]
    Non-alcoholic fatty liver disease (NAFLD) is characterized by the hepatic manifestation of metabolic syndrome and is the leading cause of chronic liver disease. Steatohepatitis plays a critical role in the process resulting in liver fibrosis and cirrhosis. Puerarin is a herbal product widely used in Asia, and is believed to have therapeutic benefits for alleviating the symptoms of steatohepatitis.
    The present study was designed to investigate the effects and mechanisms of action of Puerarin in reducing lipid accumulation in oleic acid (OA)-treated HepG2 cells. Hepatocytes were treated with OA with or without Puerarin to observe lipid accumulation by Oil Red O staining. We also examined hepatic lipid contents (e.g., triacylglycerol and cholesterol) following treatment with Puerarin. Western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR) were used to measure sterol regulatory element binding protein (SREBP)-1, fatty acid synthase (FAS), peroxisome proliferator-activated receptor α (PPARα) and adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) protein and mRNA expression, respectively. Our results revealed that Puerarin suppressed OA-induced lipid accumulation, and reduced the triacylglycerol and cholesterol levels. Furthermore, Puerarin decreased the expression levels of lipogenic enzymes, such as FAS and SREBPs, and increased the expression levels of PPARα, which are critical regulators of hepatic lipid metabolism through the AMPK signaling pathway. These results indicate that Puerarin has the same ability to activate AMPK, and reduce SREBP-1 and FAS expression, thus inhibiting hepatic lipogenesis and increasing hepatic antioxidant activity.
    We found that Puerarin exerted a regulatory effect on lipid accumulation by decreasing lipogenesis in hepatocytes. Therefore, Puerarin extract may have therapeutic benefits in the treatment of fatty liver and lipid-related metabolic disorders.
    In vivo:
    Life Sci. 2006 Jun 20;79(4):324-30.
    Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats.[Pubmed: 16472823 ]
    Hypercholesterolemia is a dominant risk factor for the development and progression of atherosclerosis and cardiovascular diseases. Natural compounds have been proved to be useful in lowering serum cholesterol to slow down the progression of cardiovascular diseases. Pueraria lobata is employed clinically to treat cardiovascular diseases in China.
    In the present study, the atheroscleroprotective potential of the herb's major active compound, Puerarin, was investigated by monitoring serum lipid profile and major enzyme expressions on cholesterol homeostasis in Sprague-Dawley rats fed with control diet, hypercholesterolmic diet or hypercholesterolmic diet plus administration of Puerarin (300 mg/kg/day, p.o.) for 4 weeks. Puerarin markedly attenuated the increased total cholesterol induced by hypercholesterolmic diet in both serum and liver. It caused a significant reduction in the atherogenic index. Expression of mRNA for hepatic 7alpha-hydroxylase (CYP7A1) was significantly enhanced but not for those of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) and lanosterol 14alpha-demethylase (CYP51). To further explore the atheroscleroprotective potential of Puerarin, acetylcholine induced endothelium-dependent vasorelaxation and endothelial nitric oxide synthase (eNOS) expression on isolated thoracic aortas were analyzed. Animals administered with Puerarin suppressed the hypercholesterolemic diet induced impairment of eNOS expression, whereas there was no significant difference in the endothelium-dependent vasorelaxation among various groups of animals.
    These data indicated that Puerarin reduced the atherogenic properties of dietary cholesterol in rats. Its hypocholesterolemic function may be due to the promotion of cholesterol and bile acids excretion in liver. Whether Puerarin targets directly on cholesterol homeostasis or both cholesterol homeostasis and endothelial function remains to be determined.
    Puerarin Description
    Source: The roots of Pueraria lobata
    Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN92172
    CAS No: 22688-79-5
    Price: $318/10mg

    Catalog No: CFN95039
    CAS No: 58880-25-4
    Price: $318/10mg

    Catalog No: CFN95047
    CAS No: 35589-22-1
    Price: $413/5mg
    Gymnoside III

    Catalog No: CFN95033
    CAS No: 899430-03-6
    Price: $418/10mg
    Decursitin D

    Catalog No: CFN95002
    CAS No: 245446-61-1
    Price: $388/5mg
    Parishin A

    Catalog No: CFN93112
    CAS No: 62499-28-9
    Price: $120/20mg

    Catalog No: CFN99295
    CAS No: 118916-57-7
    Price: $388/5mg
    Lithospermic acid

    Catalog No: CFN98546
    CAS No: 28831-65-4
    Price: $138/20mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.4017 mL 12.0083 mL 24.0165 mL 48.033 mL 60.0413 mL
    5 mM 0.4803 mL 2.4017 mL 4.8033 mL 9.6066 mL 12.0083 mL
    10 mM 0.2402 mL 1.2008 mL 2.4017 mL 4.8033 mL 6.0041 mL
    50 mM 0.048 mL 0.2402 mL 0.4803 mL 0.9607 mL 1.2008 mL
    100 mM 0.024 mL 0.1201 mL 0.2402 mL 0.4803 mL 0.6004 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Cell Research:
    Mol Vis. 2014 Dec 31;20:1815-23. eCollection 2014.
    The effect of puerarin against IL-1β-mediated leukostasis and apoptosis in retinal capillary endothelial cells (TR-iBRB2).[Pubmed: 25593509]
    Blood-retinal barrier (BRB) breakdown, the early hallmark of diabetic retinopathy (DR), is thought to depend on retinal inflammation and cell damage. The proinflammatory factor interleukin-1β (IL-1β) was demonstrated to cause inflammation as well as cell apoptosis during the process of BRB breakdown. This study extensively evaluated the protective effect of Puerarin, a major active component extracted from the traditional herb Radix puerariae, against IL-1β-induced cell dysfunction in TR-iBRB2 cells, a retinal capillary endothelial cell line.
    TR-iBRB2 cells were pretreated with IL-1β (10 ng/ml) for 24 h and then exposed to Puerarin (0, 10, 25, and 50 μM) for another 24 h. Leukocyte endothelial adhesion was assessed through a cell-based assay using lymphoblastoid cells. Cell apoptosis was evaluated with flow cytometry, and the expression of adhesion molecules and apoptosis-related molecules was assessed with western blot analysis. Our data showed that Puerarin attenuated IL-1β-mediated leukostasis and cell apoptosis in TR-iBRB2 cells. Furthermore, Puerarin strikingly prevented IL-1β-induced molecular events of the upstream and downstream signaling pathways involved in this cellular process.
    These findings may significantly contribute to better understanding of the protective effect of Puerarin, in particular for DR, as well as provide novel insights into the potential application of this compound in DR therapy.
    Cell Biol Int. 2008 Oct;32(10):1230-7.
    Puerarin protects PC12 cells against beta-amyloid-induced cell injury.[Pubmed: 18675923 ]
    beta-Amyloid protein (Abeta), a major protein component of brain senile plaques in Alzheimer's disease, is known to be directly responsible for the production of reactive oxygen species (ROS) and induction of apoptosis.
    In this study, the protective effect of Puerarin, an isoflavone purified from the radix of the Chinese herb Pueraria lobata, on Abeta-induced rat pheochromocytoma (PC12) cultures was investigated. Although exposure of PC12 cells to 50 microM Abeta25-35 caused significant viability loss and apoptotic rate increase, pretreatment of the cells with Puerarin for 24h reduced the viability loss and apoptotic rate. Puerarin (1 microM) significantly inhibited Abeta25-35-induced apoptosis of PC12 cells. Preincubation of the cell with Puerarin also restored the ROS and mitochondrial membrane potential levels that had been altered as a result of Abeta25-35 treatment. Puerarin was also found to increase the Bcl-2/Bax ratio and reduce caspase-3 activation.
    These results suggest that Puerarin could attenuate Abeta25-35-induced PC12 cell injure and apoptosis and could also promote the survival of PC12 cells. Therefore, Puerarin may act as an intracellular ROS scavenger, and its antioxidant properties may protect against Abeta25-35-induced cell injury.
    Animal Research:
    Immunol Lett. 2015 Feb;163(2):173-8.
    Puerarin attenuates airway inflammation by regulation of eotaxin-3.[Pubmed: 25530546]
    Puerarin is an isoflavonoid isolated from the root of the plant Pueraria lobata and has been used as a prescribed drug in China for the treatment of many diseases in the clinical practice.
    The present study aimed to determine the protective effects and the underlying mechanisms of Puerarin on ovalbumin (OVA)-induced allergic inflammation in a mouse model of allergic asthma. Asthma mice model was established by ovalbumin. A total of 50 mice were randomly assigned to five experimental groups: control, model, dexamethasone (2 mg/kg), and Puerarin (10 mg/kg, 20 mg/kg). Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by hematoxylin and eosin (HE) staining, BALF levels of Th1/Th2 cytokines were measured by enzyme-linked immunosorbent assay, eotaxin-3 was evaluated by western blotting. Our study demonstrated that, compared with model group, Puerarin inhibited OVA-induced increases in Raw and eosinophil count; interleukin (IL)-4, IL-5, IL-13 levels were recovered in bronchoalveolar lavage fluid compared; increased IFN-γ level in bronchoalveolar lavage fluid; histological studies demonstrated that Puerarin substantially inhibited OVA-induced eosinophilia in lung tissue compared with model group. Western blotting studies demonstrated that Puerarin substantially inhibited eotaxin-3 compared with model group.
    Our findings support Puerarin can prevent some signs of allergic asthma in the mouse model.
    J Surg Res. 2014 Jan;186(1):328-37.
    Puerarin ameliorates oxidative stress in a rodent model of traumatic brain injury.[Pubmed: 24079811 ]
    A wealth of evidence has suggested that oxidative stress is involved in the secondary brain injury after traumatic brain injury (TBI). Recently, numerous in vivo and in vitro studies were reported that Puerarin could inhibit oxidative stress through the activation of phosphatidylinositol 3-kinase (PI3K)-Akt pathway. It is unknown, however, whether Puerarin can provide neuroprotection and reduce oxidative stress after TBI. The present study investigated the effects of Puerarin on the TBI-induced neurodegeneration, oxidative stress, and the possible role of PI3K-Akt pathway in the neuroprotection of Puerarin, in a rat model of TBI.
    Rats were randomly distributed into various subgroups undergoing the sham surgery or TBI procedures. Puerarin (200 mg/kg) was given intraperitoneally at 10 min before injury and PI3K-Akt pathway inhibitor LY294002 was also administered intracerebroventricular in one subgroup. All rats were killed at 24 h after TBI for examination. Our data indicated that Puerarin could significantly reduce TBI-induced neuronal degeneration, accompanied by the partial restoration of the redox disturbance and enhanced expression of phospho-Akt in the pericontusional cortex after TBI. Moreover, PI3K-Akt pathway inhibitor LY294002 could partially abrogate the neuroprotection of Puerarin in rats with TBI.
    These results indicate that Puerarin can ameliorate oxidative neurodegeneration after TBI, at least in part, through the activation of PI3K-Akt pathway.